Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...

Nevertheless, in the past year, Merck (MRK) delivered an impressive 73% return to investors, outpacing the S&P 500. The peak ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced ...

Moderna and Merck's neoantigen treatment, combining a personalized mRNA cancer vaccine with the immunotherapy drug ...

El tratamiento experimental se administra tras la cirugía y busca reducir el riesgo de recaída y metástasis en pacientes con ...

Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so ...

The experimental mRNA vaccine successfully cleared phase 3 clinical trials, the last step necessary before it can be approved ...

Merck and Moderna's mRNA cancer vaccine hit its Phase 3 trial endpoint, showing improved recurrence-free survival in melanoma ...

President Donald Trump’s announcement this week of White House aide Heidi Overton as his pick to lead the FDA gave the pharma ...

Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the ...

Early results from final-stage trial of individualised melanoma jab offer hope of more tailor-made cancer treatments ...

MRK's Keytruda remains a key growth engine in 2026, but patent loss and rising competition could challenge its long-term ...